Nivolumab in Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck: Efficacy and Safety in CheckMate 141 by Prior Cetuximab Use
Top Cited Papers
Open Access
- 1 September 2019
- journal article
- research article
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 25 (17), 5221-5230
- https://doi.org/10.1158/1078-0432.ccr-18-3944
Abstract
Purpose: Cetuximab, which modulates immune responses, may affect the efficacy of subsequent immunotherapy. Here, we assessed outcomes with nivolumab, by prior cetuximab exposure, in patients with recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN) who had experienced progression within 6 months of platinum-containing chemotherapy. Patients and Methods: In the randomized, open-label, phase III CheckMate 141 trial, patients were randomized 2:1 to nivolumab 3 mg/kg every 2 weeks or investigator's choice (IC) of single-agent chemotherapy, with stratification by prior cetuximab exposure. The primary endpoint was overall survival (OS); additional endpoints were progression-free survival, objective response rate, and safety. Results: In patients with prior cetuximab exposure, the median OS was 7.1 months with nivolumab versus 5.1 months with IC (HR, 0.84; 95% CI, 0.62–1.15); OS benefit with nivolumab was maintained across most demographic subgroups. In patients without prior cetuximab exposure, the median OS was 8.2 months with nivolumab versus 4.9 months with IC (HR, 0.52; 95% CI, 0.35–0.77); OS benefit with nivolumab was maintained across patient baseline subgroups including tumor programmed death ligand 1 (PD-L1) expression (Conclusions: Nivolumab appeared to improve efficacy versus IC regardless of prior cetuximab use, supporting its use in patients with R/M SCCHN with or without prior cetuximab exposure. The reduction in risk of death with nivolumab compared with IC was greater in patients without prior cetuximab exposure versus with prior cetuximab exposure.Keywords
Other Versions
Funding Information
- NIH (P50 CA097190-14, P30 CA047904-28, R01 CA206517)
- NIH (P30 CA016672)
This publication has 23 references indexed in Scilit:
- Cetuximab ameliorates suppressive phenotypes of myeloid antigen presenting cells in head and neck cancer patientsJournal for ImmunoTherapy of Cancer, 2015
- CTLA-4+ Regulatory T Cells Increased in Cetuximab-Treated Head and Neck Cancer Patients Suppress NK Cell Cytotoxicity and Correlate with Poor PrognosisCancer Research, 2015
- Immune biomarkers of anti-EGFR monoclonal antibody therapyAnnals of Oncology, 2014
- EGFR-mediated tumor immunoescapeOncoImmunology, 2013
- Cetuximab-Activated Natural Killer and Dendritic Cells Collaborate to Trigger Tumor Antigen–Specific T-cell Immunity in Head and Neck Cancer PatientsClinical Cancer Research, 2013
- A view on EGFR-targeted therapies from the oncogene-addiction perspectiveFrontiers in Pharmacology, 2013
- Treatment options for patients with recurrent or metastatic squamous cell carcinoma of the head and neck, who progress after platinum-based chemotherapyCurrent Opinion in Oncology, 2012
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)European Journal Of Cancer, 2009
- Platinum-Based Chemotherapy plus Cetuximab in Head and Neck CancerNew England Journal of Medicine, 2008
- Status of Epidermal Growth Factor Receptor Antagonists in the Biology and Treatment of CancerJournal of Clinical Oncology, 2003